Literature DB >> 21421285

Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α.

Wenjing Su1, Lei Huang, Qilin Ao, Qinghua Zhang, Xun Tian, Yong Fang, Yunping Lu.   

Abstract

Hypoxia-inducible factor 1 alpha (HIF-1α) is closely related with chemoresistance of solid tumors. The purpose of this study was to investigate the ability of noscapine to inhibit HIF-1α and sensitize ovarian cancer cells to cisplatin (DDP) under hypoxic conditions. Herein, we report that noscapine sensitized cobalt-induced chemoresistant ovarian cancer cells to DDP-induced apoptosis and inhibition of cell proliferation. Noscapine also promoted proteasome-mediated degradation of cobalt-stabilized HIF-1α protein, with subsequent inhibition of HIF-1 transcriptional activity. These data establish noscapine as a small molecule inhibitor of HIF-1α and provide an evidence for its combination with DDP in combating ovarian cancer chemoresistance.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421285     DOI: 10.1016/j.canlet.2011.02.031

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications.

Authors:  Padmashree C G Rida; Dillon LiVecche; Angela Ogden; Jun Zhou; Ritu Aneja
Journal:  Med Res Rev       Date:  2015-07-14       Impact factor: 12.944

Review 2.  Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective.

Authors:  Francisco Javier Rodríguez-Jiménez; Victoria Moreno-Manzano
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

3.  HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer.

Authors:  Yanbin Liu; Amanda M Bernauer; Christin M Yingling; Steven A Belinsky
Journal:  Carcinogenesis       Date:  2012-03-31       Impact factor: 4.944

4.  Bitter taste receptors are expressed in human epithelial ovarian and prostate cancers cells and noscapine stimulation impacts cell survival.

Authors:  Louis T P Martin; Mark W Nachtigal; Tamara Selman; Elaine Nguyen; Jayme Salsman; Graham Dellaire; Denis J Dupré
Journal:  Mol Cell Biochem       Date:  2018-10-22       Impact factor: 3.396

5.  Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.

Authors:  Agata Zemła; Irmina Grzegorek; Piotr Dzięgiel; Karolina Jabłońska
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

6.  BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts.

Authors:  Linda Helbig; Lydia Koi; Kerstin Brüchner; Kristin Gurtner; Holger Hess-Stumpp; Kerstin Unterschemmann; Michael Baumann; Daniel Zips; Ala Yaromina
Journal:  Radiat Oncol       Date:  2014-09-19       Impact factor: 3.481

7.  The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.

Authors:  Scott W Malm; Neale T Hanke; Alexander Gill; Liliana Carbajal; Amanda F Baker
Journal:  J Exp Clin Cancer Res       Date:  2015-04-01

8.  Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.

Authors:  Peter Andorfer; Alexander Heuwieser; Andreas Heinzel; Arno Lukas; Bernd Mayer; Paul Perco
Journal:  BMC Syst Biol       Date:  2016-04-18

Review 9.  The fate of chemoresistance in triple negative breast cancer (TNBC).

Authors:  Elma A O'Reilly; Luke Gubbins; Shiva Sharma; Riona Tully; Matthew Ho Zhing Guang; Karolina Weiner-Gorzel; John McCaffrey; Michele Harrison; Fiona Furlong; Malcolm Kell; Amanda McCann
Journal:  BBA Clin       Date:  2015-03-12

10.  SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.

Authors:  Qilin Ao; Wenjing Su; Shuang Guo; Lei Cai; Lei Huang
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.